Are Analysts Bullish Retrophin Inc (NASDAQ:RTRX) After Last Week?

October 12, 2017 - By Marguerite Chambers

 Are Analysts Bullish Retrophin Inc (NASDAQ:RTRX) After Last Week?
Investors sentiment increased to 1.16 in 2017 Q2. Its up 0.18, from 0.98 in 2017Q1. It is positive, as 13 investors sold Retrophin Inc shares while 31 reduced holdings. 13 funds opened positions while 38 raised stakes. 39.61 million shares or 0.01% more from 39.61 million shares in 2017Q1 were reported.
Secor Advisors L P owns 35,514 shares. 1.02 million were reported by Oak Ridge Llc. Pub Employees Retirement Association Of Colorado reported 10,796 shares or 0% of all its holdings. Wells Fargo Mn owns 39,511 shares or 0% of their US portfolio. State Board Of Administration Of Florida Retirement Sys holds 0% or 23,645 shares. Products Prtn Ltd has invested 0.12% in Retrophin Inc (NASDAQ:RTRX). Fincl Bank Of Montreal Can owns 113,184 shares or 0% of their US portfolio. 47,545 are owned by Aqr Cap Management Ltd. Dekabank Deutsche Girozentrale holds 20,300 shares or 0% of its portfolio. Senzar Asset Management Ltd holds 1.18% or 246,289 shares in its portfolio. Carroll Financial Assoc Inc has invested 0% in Retrophin Inc (NASDAQ:RTRX). Manufacturers Life Ins Co The stated it has 30,077 shares. holds 0% or 23,717 shares. Emory University accumulated 91,108 shares. Millennium Ltd Liability Corporation holds 0.01% or 288,098 shares.

Since June 14, 2017, it had 1 buying transaction, and 0 sales for $89,250 activity.

Retrophin Inc (NASDAQ:RTRX) Ratings Coverage

Among 4 analysts covering Retrophin (NASDAQ:RTRX), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Retrophin had 6 analyst reports since August 12, 2015 according to SRatingsIntel. The rating was initiated by BMO Capital Markets on Tuesday, April 12 with “Outperform”. JMP Securities initiated the shares of RTRX in report on Monday, November 2 with “Mkt Outperform” rating. The rating was maintained by BMO Capital Markets on Friday, October 6 with “Buy”. Zacks downgraded the shares of RTRX in report on Wednesday, August 12 to “Buy” rating. Below is a list of Retrophin Inc (NASDAQ:RTRX) latest ratings and price target changes.

06/10/2017 Broker: BMO Capital Markets Rating: Buy New Target: $44.0 Maintain

About 36,470 shares traded. Retrophin Inc (NASDAQ:RTRX) has risen 4.93% since October 12, 2016 and is uptrending. It has underperformed by 11.77% the S&P500.

Retrophin, Inc. is a biopharmaceutical company. The company has market cap of $936.41 million. The Firm is focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. It currently has negative earnings. The Firm sells three products, including Chenodal , Cholbam (cholic acid) and Thiola (tiopronin).

Another recent and important Retrophin Inc (NASDAQ:RTRX) news was published by Globenewswire.com which published an article titled: “Retrophin Announces Presentation of New Data from Physician-Initiated …” on October 05, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.